Evidence map›Paper›PMID 35338088›Full record

Trial reportJournal for immunotherapy of cancer2022

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.

Jun Liu, Yang Yang, Zhichao Liu, Xiaolong Fu, Xiaoyue Cai, Hongxuan Li, Li Zhu, Yan Shen, Hong Zhang, Yifeng Sun and 6 more

Erratum issued 2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 199 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 10 pooled it
53.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06225921 phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

The Safety and Feasibility of Neoadjuvant Adebrelimab With Dalpiciclib for the Treatment of Resectable Esophageal Squamous Cell Carcinoma：A Phase 1 Trial

TypeinterventionalSponsorWest China HospitalRan2023 to 2025Enrolled6ConditionsEsophageal Squamous Cell CarcinomaArmsAdebrelimab, Dalpiciclib 100mg, Dalpiciclib 150mg
NCT06863831 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Yishen Qutong Granules vs. Simulant Combined With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy in the Treatment of Locally Advanced Esophageal Cancer: A Multicenter, Prospective, Double-Blind, Randomized Controlled Trial Protocol

TypeinterventionalSponsorCancer Institute and Hospital, Chinese Academy of Medical SciencesRan2024 to 2027Enrolled536ConditionsEsophageal Squamous Cell Carcinoma (ESCC)ArmsYishen Qutong Granules, Yishen Qutong Simulant Granules
3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 10 syntheses or guidelines pooled it, 265 citations in OpenAlex.

  1. Pooled it
  2. Adjuvant immunotherapyFrontiers in immunology · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Jun LiuDepartment of Radiation Oncology, Shanghai Jiao Tong University, Shanghai, China.
Yang YangDepartment of Thoracic Surgery, Shanghai Jiao Tong University, Shanghai, China.
Zhichao LiuDepartment of Thoracic Surgery, Shanghai Jiao Tong University, Shanghai, China.ORCID 0000-0003-3542-0905
Xiaolong FuDepartment of Radiation Oncology, Shanghai Jiao Tong University, Shanghai, China.
Xiaoyue CaiDepartment of Integrative Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hongxuan LiDepartment of Radiation Oncology, Shanghai Jiao Tong University, Shanghai, China.
Li ZhuDepartment of Radiology, Shanghai Jiao Tong University, Shanghai, China.
Yan ShenDepartment of Radiology, Shanghai Jiao Tong University, Shanghai, China.
Hong ZhangDepartment of Thoracic Surgery, Shanghai Jiao Tong University, Shanghai, China.
Yifeng SunDepartment of Thoracic Surgery, Shanghai Jiao Tong University, Shanghai, China.
Hezhong ChenDepartment of Thoracic Surgery, Changhai Hospital, Shanghai, China.
Bentong YuDepartment of Thoracic Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Renquan ZhangDepartment of Thoracic Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jinchen ShaoDepartment of Pathology, Shanghai Jiao Tong University, Shanghai, China.
Ming ZhangDepartment of Integrative Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhigang LiDepartment of Thoracic Surgery, Shanghai Jiao Tong University, Shanghai, China zhigang.li@shsmu.edu.cn.ORCID 0000-0001-5086-5334
Shanghai Jiao Tong University · CNAnhui Medical University · CNNanchang University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCamrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). This study aimed to evaluate the safety and efficacy of camrelizumab plus neoadjuvant chemotherapy, using pathologically complete response (pCR) as primary endpoint, in the treatment for locally advanced ESCC.

methodsPatients with locally advanced but resectable thoracic ESCC, staged as T1b-4a, N2-3 (≥3 stations), and M0 or M1 lymph node metastasis (confined to the supraclavicular lymph nodes) were enrolled. Eligible patients received intravenous camrelizumab (200 mg, day 1) plus nab-paclitaxel (100 mg/m

resultsFrom November 20, 2019 to December 22, 2020, 60 patients were enrolled. 55 (91.7%) patients completed the full two-cycle treatment successfully. 51 patients underwent surgery and R0 resection was achieved in 50 (98.0%) patients. pCR (ypT0N0) was identified in 20 (39.2%) patients and 5 (9.8%) patients had complete response of the primary tumor but residual disease in lymph nodes alone (ypT0N+). 58 patients (96.7%) had any-grade treatment-related adverse events (TRAEs), with the most common being leukocytopenia (86.7%). 34 patients (56.7%) had adverse events of grade 3 or worse, and one patient (1.7%) occurred a grade 5 adverse event. There was no in-hospital and postoperative 30-day as well as 90-day mortality.

conclusionsThe robust antitumor activity of camrelizumab and chemotherapy was confirmed and demonstrated without unexpected safety signals. Our findings established camrelizumab and chemotherapy as a promising neoadjuvant treatment for locally advanced ESCC. TRIAL REGISTRATION NUMBER: ChiCTR1900026240.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHumansNeoadjuvant TherapyAntibodies, Monoclonal, HumanizedcamrelizumabClinical Trials, Phase II as TopicCombined Modality TherapyImmunotherapy

Identifiers

PMID35338088
PMCPMC8961177
OpenAlexW4220823757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.